This seminar was the first in our "A Vaccine for" seminar series, in which leading experts will provide an overview of the state of vaccine research for VAIDATE’s focus pathogens.
In this seminar, Prof Mitali Chatterjee and Dr Mohamed Osman provided an overview and update on the current state of research into vaccines for leishmaniasis. Leishmaniasis refers to a diverse group of diseases, all caused by single-celled parasites called Leishmania. Over 1 billion people worldwide are at risk of leishmaniasis at any given time; about 12 million people are infected at any one time, causing 20,000-40,000 deaths annually.
The seminar is especially interesting to vaccine researchers who do not study leishmaniasis.
Prof Mitali Chatterjee is a Professor of Pharmacology, Institute of Postgraduate Medical Education & Research (IPGMER), India. Mitali leads a group at IPGMER that has developed a DNA based assays for diagnosis and monitoring of PKDL, and as part of the ongoing Leishmaniasis ‘active surveillance’ programme in West Bengal, her laboratory serves as the nodal centre that provides information regarding parasite load, a key marker for measuring chemotherapeutic effectiveness. In 2015, Mitali was elected a Fellow of the National Academy of Sciences, India and in 2017 as a Fellow of the Indian Academy of Sciences.
Dr Mohamed Osman is a Post-doctoral Researcher at the University of York, UK and a visiting Professor at Khartoum University, Sudan. Mohammed's area of interest is vaccine development and evaluation both in animal models and by conducting clinical trials. He has conducted a number of clinical trials both in UK and Sudan, against leishmania and CMV.